Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
1,384
Views
3
CrossRef citations to date
0
Altmetric
Infectious Diseases

Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS

Maricela Valerioa Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain;b Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain;c Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain;d Facultad de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón, CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Universidad Complutense de Madrid, Madrid, SpainORCID Iconhttps://orcid.org/0000-0001-6394-2861
ORCID Icon,
Cristina Veintimillaa Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, SpainORCID Iconhttps://orcid.org/0000-0003-4601-7601
ORCID Icon,
Carmen Rodríguezb Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain;e Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1046-8830
ORCID Icon,
Sofía de la Villaa Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, SpainORCID Iconhttps://orcid.org/0000-0002-1371-6417
ORCID Icon,
Mar Sánchez-Somolinosa Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
,
Mónica Cerezalesf Axentiva Solutions S.L., Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-6705-006X
ORCID Icon,
Carlos Crespof Axentiva Solutions S.L., Barcelona, Spain;g Departamento de G.M estadística, Universidad de Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-6066-0818
ORCID Icon,
Sara Rodrígueza Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain;b Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, SpainORCID Iconhttps://orcid.org/0000-0003-1612-4772
ORCID Icon,
Iván Adána Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
,
Esther Chamorrob Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain;e Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, SpainORCID Iconhttps://orcid.org/0000-0002-2654-7165
ORCID Icon,
Irantzu Rossellóh Angelini Pharma España, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-1955-9213
ORCID Icon &
Patricia Muñoza Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain;b Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain;c Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain;d Facultad de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón, CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Universidad Complutense de Madrid, Madrid, SpainORCID Iconhttps://orcid.org/0000-0001-5706-5583
ORCID Icon show all
Pages 463-472 | Received 04 Nov 2022, Accepted 10 Mar 2023, Published online: 31 Mar 2023

References

  • Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis; 2016;29(2):109–115.
  • Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19(9):E377–85.
  • Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol. 2012;50:238–245.
  • European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) – annual epidemiological report 2019AER for 2019. Stockholm; 2020.
  • European Medicines Agency. EPAR: Xydalba, dalbavancin hydrochloride – Europa EU. 2017.
  • Streifel AC, Sikka MK, Bowen CD, et al. Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019;54:652–654.
  • Morrisette T, Miller MA, Montague BT, et al. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019;74:2405–2416.
  • Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210–214.
  • Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51:571–577.
  • Fajardo AC, Sanz EU, Muñoz CG. Dalbavancin in the treatment of skin and soft tissues infection. Farm. Hosp. Sociedad Espanola de Farmacia Hospitalaria; 2017;642–643.
  • Rodríguez-Pardo D. Evaluación de la evidencia clínica con dalbavancina. Enferm Infecc Microbiol Clin. 2017;35:33–37.
  • Gray A, Clarke P, Wolstenholme J, et al. Applied methods of cost-effectiveness analysis in healthcare. Oxford: Oxford University Press; 2010.
  • Jeffres MN. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017;77:1143–1154.
  • Azzouz A, Preuss C V. Linezolid. Treasure Island, FL: StatPearls Publishing; 2021.
  • Dinh A, Duran C, Pavese P, et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents. 2019;54:668–672.
  • Marcellusi A, Viti R, Sciattella P, et al. Economic evaluation of the treatment of acute bacterial skin and skin structure infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries. Expert Rev Pharmacoeconomics Outcomes Res. 2019;19:581–599.
  • Agarwal R, Bartsch SM, Kelly BJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361–368.
  • Krsak M, Morrisette T, Miller M, et al. Advantages of outpatient treatment with long‐acting lipoglycopeptides for serious gram‐positive infections: a review. Pharmacother J Hum Pharmacol Drug Ther. 2020;40:469–478.
  • Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019;8:171–184.
  • Poliseno M, Bavaro DF, Brindicci G, et al. Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different gram-positive bacterial infections. Clin Drug Investig. 2021;41(5):437–448.
  • Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18(1):30.
  • Marcellusi A, Bini C, Andreoni M, et al. Budget impact analysis of dalbavancin in the treatment of acute bacterial skin and skin structure infections in three European countries. Clin Drug Investig. 2020;40:305–318.
  • Bouza E, Alonso S, Asensio Á, et al. Information on nosocomial infections in the mainstream media: an opinion document. Rev Esp Quim. 2019;32:165–177.
  • Turco NJ, Kane-Gill SL, Hernández I, et al. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections. Expert Opin Pharmacother. 2018;19:319–325.
  • McCarthy MW, Keyloun KR, Gillard P, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE TRIAL. Infect Dis Ther. 2020;9:67.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.